博雅生物(300294) - 2025年8月23日投资者关系活动记录表

Financial Performance - In the first half of 2025, the company achieved a consolidated revenue of CNY 1.008 billion, an increase of CNY 112 million, representing a year-on-year growth of 12.51% [2][3] - The raw plasma collection volume increased by 7.2% year-on-year, surpassing the industry average growth rate [3][10] Product Development and Market Strategy - The company successfully obtained approval for the clinical trial of subcutaneous immunoglobulin (皮丙) in April 2025, positioning itself among the top three in the domestic market for this product [5][6] - The 10% intravenous immunoglobulin (静丙) was officially approved for market entry in May 2025, with a strong academic promotion strategy in place [7][15] - The company is focusing on enhancing its marketing strategies and academic promotion to address clinical pain points and ensure proper medication use [7][14] International Expansion - The company has made significant strides in international markets, obtaining drug registration certificates in the Dominican Republic and Turkey for its products [3][15] - The internationalization strategy includes targeting markets with regulatory systems similar to China's before advancing to stricter markets like Europe and the US [15] Supply Chain and Production - The company maintained a balanced production and sales for its core products, with inventory levels remaining reasonable [4] - The overall plasma collection volume reached 320.39 tons in the first half of 2025, with a year-on-year growth of 7.2% [10] Regulatory and Market Challenges - The company is adapting to the ongoing changes in the blood product procurement policies, which are gradually expanding in scope and variety [13][14] - The impact of the introduction of recombinant human albumin on the market is being monitored, as both recombinant and human-derived albumin play significant roles in clinical applications [12] Future Outlook - The company is committed to becoming a world-class blood product enterprise, focusing on core competencies and optimizing product structure [18] - Plans for expanding plasma collection stations are in place, although approvals from various government levels may introduce uncertainties [11]